Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Year: 2025
Type: article
Abstract: Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the clinical trial CheckMate-067 and the International Germline Immuno-Oncology Melanoma Consortium. We discovered and validated significant associations of MT haplogroup T (HG-T) with resistance to anti-programmed cell death protein-1-based ICI (both single-agent and combination) and have shown that HG-T is independent from established tumor predictors. We also found that patients belonging to HG-T exhibit a unique nivolumab-resistant baseline peripheral CD8+ T cell repertoire compared to other MT haplogroups, providing, to our knowledge, the first link between MT inheritance, host immunity and ICI resistance. The study proposes a host blood-based biomarker with stand-alone clinical value predicting ICI efficacy and points to an ICI-resistance mechanism associated with MT metabolism, with clinical relevance in immuno-oncology.
Source: Nature Medicine
Authors: Kelsey R. Monson, Robert Ferguson, Joanna E. Handzlik, Leah Morales, Jiahan Xiong, Vylyny Chat, Sasha Dagayev, Alireza Khodadadi-Jamayran, Danny Simpson, Esther Kazlow, Anabelle Bunis, Chaitra Sreenivasaiah, Milad Ibrahim, Iryna Voloshyna, Wouter Ouwerkerk, Rosalie M. Luiten, Mariaelena Capone, Gabriele Madonna, Yuting Lu, Yongzhao Shao, Anna Pavlick, Michelle Krogsgaard, Janice Mehnert, Hao Tang, Sonia Dolfi, Daniel Tenney, John B. A. G. Haanen, Thomas F. Gajewski, F. Stephen Hodi, Keith T. Flaherty, Kasey Couts, William Robinson, Igor Puzanov, Marc S. Ernstoff, Osama Rahma, Michael Postow, Ryan J. Sullivan, Jason J. Luke, Paolo A. Ascierto, Iman Osman, Tomas Kirchhoff
Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Weill Cornell Medicine, New York University, New York Genome Center, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam institute for Immunology and Infectious Diseases, University of Amsterdam, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Cornell University, Bristol-Myers Squibb (United States), The Netherlands Cancer Institute, University of Chicago, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital, University of Colorado Anschutz, Roswell Park Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
Awards: G1007166040, G1700102955, G2224338489, Germline biomarkers of melanoma immunotherapy: an international consortium, G4206891758, G480045316, (8) Genomic determinants of the T-cell regulome in immune checkpoint blockade, NYU Melanoma SPORE, Transcriptional Regulation of Peripheral Immune Cells as a Modulator of Melanoma Immunotherapy Resistance and Toxicity, Cancer Center Support Grant, Tri-Institutional PhD Program in Computational Biology & Medicine, Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer
OpenAlex ID: W4411069151
